Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

58.12USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$58.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
133,198
52-wk High
$74.75
52-wk Low
$47.25

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals Files Supplement Related To Offering Of 329,124 Shares By Selling Stockholders - SEC Filing
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS INC FILES PROSPECTUS SUPPLEMENT RELATES TO OFFERING OF 329,124 SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Aerie Pharmaceuticals Q2 GAAP Loss Per Share $1.40
Wednesday, 8 Aug 2018 

Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 ADJUSTED LOSS PER SHARE $1.14.Q2 GAAP LOSS PER SHARE $1.40.Q2 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.AERIE PHARMACEUTICALS - $286.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30.AERIE PHARMACEUTICALS - REITERATED 2018 RHOPRESSA NET REVENUES, TOTAL 2018 CASH BURN GUIDANCE.  Full Article

Aerie Pharmaceuticals And DSM Biomedical Expand Collaboration Agreement
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS, INC. AND DSM BIOMEDICAL, INC. EXPAND COLLABORATION AGREEMENT FOCUSED ON NOVEL DRUG DELIVERY TECHNOLOGY IN OPHTHALMOLOGY.AERIE PHARMACEUTICALS - PAID $6.0 MILLION TO DSM UPON SIGNING OF EXPANDED AGREEMENT, WITH AN ADDITIONAL $9.0 MILLION PAYABLE TO DSM THROUGH END OF 2020.AERIE PHARMACEUTICALS - TO HAVE EXCLUSIVE LICENSE FOR OPHTHALMIC INDICATIONS TO DSM'S POLYESTERAMIDE POLYMER TECHNOLOGY FOR UNLIMITED NUMBER OF COMPOUNDS.AERIE PHARMACEUTICALS INC - AERIE AND DSM WILL CONTINUE COLLABORATIVE RESEARCH ACTIVITIES THROUGH END OF 2020.AERIE PHARMACEUTICALS - WILL GAIN ACCESS TO DSM'S PRECLINICAL STAGE LATANOPROST IMPLANT WITH POTENTIAL FOR INITIAL CLINICAL STUDIES IN GLAUCOMA PATIENTS IN 2019.  Full Article

Aerie Pharmaceuticals Announces Deerfield’S Conversion Of Convertible Notes Into Aerie Common Stock
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES DEERFIELD’S CONVERSION OF CONVERTIBLE NOTES INTO AERIE COMMON STOCK AND ESTABLISHMENT OF AN UNDRAWN $100M CREDIT FACILITY WITH DEERFIELD.ENTERED INTO A $100 MILLION SENIOR SECURED DELAYED DRAW TERM LOAN FACILITY WITH AFFILIATES OF DEERFIELD.CREDIT FACILITY MATURES ON JULY 23, 2024.  Full Article

Aerie Pharmaceuticals Announces Early Notification Of FDA Acceptance Of NDA Submission For Roclatan
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.  Full Article

Aerie Pharmaceuticals Announces Early Notification Of FDA Acceptance Of NDA Submission For Roclatan
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.  Full Article

Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm
Tuesday, 15 May 2018 

May 15 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%.AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS.AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW.  Full Article

Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%
Monday, 30 Apr 2018 

April 30 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%.AERIE - FORMULARY CONTRACTS FOR COMMERCIAL INSURANCE COVERAGE IN 2018, MEDICARE PART D PROGRAM COVERAGE BEGINNING 2019 IN FINAL STAGES OF EXECUTION.  Full Article

Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING.AERIE PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION.  Full Article

Aerie Pharmaceuticals Gets U.S. FDA Approval Of Glaucoma Drug
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - REMAIN ON TRACK TO FILE ROCLATAN NEW DRUG APPLICATION TO FDA IN Q2 2018.AERIE PHARMACEUTICALS - RHOPRESSA APPROVED AHEAD OF SCHEDULED PDUFA DATE OF FEBRUARY 28, 2018.  Full Article

BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm

* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%